Ixekizumab Halts Bone Damage in Axial Spondyloarthritis
TOPLINE:Ixekizumab reduced erosion and increased backfill in the sacroiliac joints of biologic disease-modifying antirheumatic drug (bDMARD)–naive patients with radiographic axial...
Erasmo Schildgen
